Skip to content
Screener

TransMedics Group, Inc. TMDX Product — Clinical Trial Expense

Similar metrics at other companies

Delcath Systems logo
DCTHClinical trial expenses
$2.45M+1.7%
Nuvectis Pharma, Inc. logo
NVCTClinical Development — Clinical Trial Expenses
$1.21M+17.0%
RFL
RFLAccrued Clinical Trial Expense
$381K
HTF
HTFLAccrued Clinical Trial Expenses Current
$1.12M
Delcath Systems logo
DCTHPrepaid Clinical Trial Expenses Current
$2.45M+1.7%
MapLight Therapeutics, Inc. logo
MPLTClinical Trial — Research And Development Expense
$24.82M+1,180%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.78B-31.3%
Enterprise value$2.73B-26.6%
P/E16.2×-40.3×
P/S4.4×-3.2×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept tmdx:ClinicalTrialExpense.

The source filing: TransMedics Group, Inc.’s 10-K, filed February 24, 2026.

Filed
Feb 24, 2026, 4:16 PM EST
Fiscal year
FY2025
Accession
0001193125-26-067032
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Gross product revenue from sales to customers$372,401$273,680$176,047
Less: clinical trial payment estimates(186)(22)
Total net product revenue$372,401$273,866$176,069

Item 8. Financial Statements and Supplementary Data.

FAQ

What is TransMedics Group, Inc.'s product — clinical trial expense?
TransMedics Group, Inc. (TMDX) reported product — clinical trial expense of $0 in Q4 2025.
How has TransMedics Group, Inc.'s product — clinical trial expense changed year-over-year?
TransMedics Group, Inc.'s product — clinical trial expense increased by 100.0% year-over-year, from -$46.5K to $0.
What is the long-term trend for TransMedics Group, Inc.'s product — clinical trial expense?
Over 4 years (2021 to 2025), TransMedics Group, Inc.'s product — clinical trial expense has grown at a -100.0% compound annual growth rate (CAGR), from $1.12M to $0.
What does product — clinical trial expense mean?
This metric tracks the specific costs associated with conducting clinical research, trials, and regulatory validation studies for products within a business segment. These expenditures are critical for demonstrating safety and efficacy to regulatory bodies to support market authorization or label expansion. High investment in this area indicates a commitment to long-term product innovation and the development of new clinical indications.

Ask your AI about TransMedics Group, Inc.'s product — clinical trial expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude